Patents Examined by Laura B Goddard
  • Patent number: 11439697
    Abstract: Cancer is treated using coordinated treatment regimens that uses various compounds and compositions that drive a tumor from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: September 13, 2022
    Assignees: NantCell, Inc., Nant Holdings IP LLC
    Inventors: Patrick Soon-Shiong, Kayvan Niazi, Shahrooz Rabizadeh, Hans G. Klingemann, Laurent H. Boissel, Barry J. Simon
  • Patent number: 11434288
    Abstract: The present invention provides for diagnostic kits for identifying cancer patients who are more susceptible to cancer therapies employing endostatin and other angiogenesis inhibitors, based upon the discovery that Nucleolin is a specific receptor for Endostatin. In particular, the diagnostic kits include antibody molecules against Nucleolin, DNA or RNA molecules that specifically bind to nucleic acid molecules encoding Nucleolin. The present invention also discloses methods of screening for angiogenesis inhibitors which specifically interact with Nucleolin, and act as angiogenesis inhibitors in an analogous manner as Endostatin. In addition, the present invention discloses methods of inhibiting the proliferation of endothelial cells or angiogenesis of tumor by administering an anti-nucleolin antibody linked to a cytotoxic agent such as tumor necrosis factor alpha to the endothelial cells.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: September 6, 2022
    Assignees: Protogen Ltd., Tsinghua University
    Inventors: Yongzhang Luo, Hubing Shi
  • Patent number: 11427632
    Abstract: Provided herein are antibodies and antigen-binding fragments thereof with low or no immunogenicity in humans and optionally with desirable manufacturing properties. Also provided are compositions comprising such antibodies or antigen-binding fragments, methods of using such antibodies, and methods for making such antibodies.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: August 30, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Jeffrey C. Johnson, Lawrence Dearth, Haralambos Hadjivassiliou, Jeonghoon Sun, Kandasamy Hariharan
  • Patent number: 11427637
    Abstract: Described herein are methods, formulations and kits for treating a patient with cancer with nanoparticle complexes comprising a carrier protein, a binding agent and paclitaxel and optionally co-treated with an anti-PD-L1 antibody.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: August 30, 2022
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 11421029
    Abstract: Provided are a recombinant bispecific antibody against CTLA-4 and PDL-1, a nucleic acid molecule for encoding the antibody, a vector and a host cell comprising the nucleic acid molecule, and a method for preparing the antibody. Also provided are a pharmaceutical composition comprising the bispecific antibody, and usage of the bispecific antibody in preparation of the pharmaceutical composition.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: August 23, 2022
    Assignee: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Tongtong Xue, Liang Xiao, Dengnian Liu, Hu Long, Jiangjiang Hu, Yamin Cui, Xiaoxi Yuan, Lichun Wang, Jingyi Wang
  • Patent number: 11413288
    Abstract: The disclosure relates to methods for treating cancers (e.g., cancers having a BRCA1 and/or BRCA2 mutation(s)) by administering to the subject an effective amount of a ubiquitin-specific protease 1 (USP1) inhibitor.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: August 16, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Alan D'Andrea, Kah Suan Lim
  • Patent number: 11407830
    Abstract: The present invention provides methods of administering certain PD-1 binding agents to patients having cancer. Dosage regimens for compositions comprising a PD-1 binding agent are also explicitly provided.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: August 9, 2022
    Assignee: Tesaro, Inc.
    Inventors: David Jenkins, Haley A Laken, Ellie Im, Allene Diaz, Sharon Lu
  • Patent number: 11401331
    Abstract: Provided are fusion molecule having a PD-L1 inhibitor fused to a human IL-7 protein or fragment thereof through a peptide linker. The disclosed fusion molecules exhibited synergistic anti-tumor effects.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: August 2, 2022
    Assignee: I-Mab Biopharma US Limited
    Inventors: Lei Fang, Feifei Cui, Haijuan Gu, Zhengyi Wang, Bingshi Guo, Jingwu Zang
  • Patent number: 11402382
    Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., kidney cancer (e.g., renal cell carcinoma (RCC)), lung cancer (e.g., non-small cell lung cancer (NSCLC)), bladder cancer (e.g., urothelial bladder cancer (UBC)), liver cancer (e.g., hepatocellular carcinoma (HCC)), ovarian cancer, or breast cancer (e.g., triple-negative breast cancer (TNBC))). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a VEGF antagonist (e.g., an anti-VEGF antibody, (e.g., bevacizumab) or a VEGFR inhibitor (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib))) and a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: August 2, 2022
    Assignee: Genentech, Inc.
    Inventors: Priti Hegde, Mahrukh Huseni
  • Patent number: 11401344
    Abstract: The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: August 2, 2022
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Weidong Huang, Jodi Weidler, Jeff Sperinde, Mojgan Haddad, Michael Bates, John William Winslow, Xueguang Jin, Gerald J. Wallweber, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Ali Mukherjee, Gordon Parry, Stephen J. Williams
  • Patent number: 11396544
    Abstract: The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human CD-22. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD-22, such as B-cell lymphomas. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: July 26, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, Dimitris Skokos, Janelle Waite, Erica Ullman, Aynur Hermann, Eric Smith, Kara Olson, Joyce Wei, George D. Yancopoulos
  • Patent number: 11391739
    Abstract: Provided by the invention are methods for identifying therapeutic agents for treating multiple myeloma or another hematological malignancy, as well as methods for determining the prognosis of a patient with multiple myeloma or another hematological malignancy. The methods are based in part on the inventors' discovery that an extracellular form of cyclophilin A binds to CD147 expressed on multiple myeloma cells.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: July 19, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Ruben Carrasco, Di Zhu
  • Patent number: 11371995
    Abstract: A method for selecting an individual to be a candidate for administration of an immune checkpoint inhibitor in treatment of a tumor, comprising: (1) a step of collecting a tumor tissue from the individual, (2) a step of determining the extent of B7-H3 expression in the tumor tissue collected in step (1), and (3) a step of selecting the individual as an individual to be a candidate for administration of the immune checkpoint inhibitor if the B7-H3 expression level is considered to be negative, is provided.
    Type: Grant
    Filed: December 25, 2017
    Date of Patent: June 28, 2022
    Assignees: Daiichi Sankyo Company, Limited, Kinki University
    Inventors: Kimio Yonesaka, Kazuhiko Nakagawa, Kenji Hirotani
  • Patent number: 11365254
    Abstract: A bispecific anti-CD3×CD19 polypeptide complex that contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety, methods of producing the bispecific anti-CD3×CD19 polypeptide complex, methods of treating disease or disorder using the bispecific anti-CD3×CD19 polypeptide complex, polynucleotides encoding the bispecific anti-CD3×CD19 polypeptide complex, vectors and host cells containing said polynucleotides, and compositions and pharmaceutical compositions comprising the bispecific anti-CD3×CD19 polypeptide complex are provided.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: June 21, 2022
    Assignee: WUXI BIOLOGICS IRELAND LIMITED
    Inventors: Jieying Liu, Jianqing Xu, Zhuozhi Wang, Qin Mei, Jing Li
  • Patent number: 11359021
    Abstract: A novel PD-L1 antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof. A humanized antibody comprising a CDR of the PD-L1 antibody, a pharmaceutical composition comprising the PD-L1 antibody and the antigen-binding fragment thereof and a use of the PD-L1 antibody as a drug. A use of a humanized PD-L1 antibody in preparing a drug for treating diseases or disorders associated with PD-L1.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: June 14, 2022
    Assignees: JIANGSU HENGRUI MEDICINE CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
    Inventors: Xiaoling Gu, Jiahua Jiang, Lei Zhang, Qiyue Hu, Jinming Gu, Weikang Tao
  • Patent number: 11359027
    Abstract: The present disclosure relates to the in vivo prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist (an anti TNFR2 antagonist antibody) (i) for use in the prevention or treatment of hematologic malignancy relapse after allogeneic hematopoietic stem cell transplantation (AHCT) or after a treatment with lymphocytes and (ii) for use in enhancing the graft-versus-leukemia-activity (GVL activity) of a hematopoietic stem cell transplantation (HCT) or a treatment with lymphocytes.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: June 14, 2022
    Assignees: UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Sébastien Maury, José Cohen, Benoît Salomon, Sina Naserian, Mathieu Leclerc
  • Patent number: 11357839
    Abstract: Brachyury protein can be used to induce Brachyury-specific CD4+ T cells in vivo and ex vivo. It is also disclosed that Brachyury protein can be used to stimulate the production of both Brachyury-specific CD4+ T cells and Brachyury-specific CD8+ T cells in a subject, such as a subject with cancer. In some embodiments, the methods include the administration of a Brachyury protein. In additional embodiments, the methods include the administration of a nucleic acid encoding the Brachyury protein, such as in a non-pox non-yeast vector. In further embodiments, the method include the administration of host cells expressing the Brachyury protein.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: June 14, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Schlom, Claudia M. Palena
  • Patent number: 11353460
    Abstract: This invention provides an antibody or functional antibody fragments, or probe thereof directed against a unique group of antigens identified in cancer. The present invention comprises nucleotide sequences derived from L2A5 monoclonal antibody. The antibody or functional antibody fragment, or probe thereof includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. This DNA/amino acid sequence conjugation is unique and has never been described before. The present invention further provides antibody or functional antibody fragment or a conjugate or a recombinant protein useful in the detection, treatment and prevention of human disease, including cancer.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: June 7, 2022
    Assignees: UNIVERSIDADE NOVA DE LISBOA, INSTITUTO PORTUGUÊS DE ONCOLOGIA DO PORTO FG, EPE, HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF—INSTITUTE OF RADIOPHARMACEUTICAL CANCER RESEARCH
    Inventors: Paula Alexandra Quintela Videira, Carlos Manuel Mendes Novo, Liliana Raquel Rodrigues Loureiro, Mylène Adelaide do Rosário Carrascal, José Alexandre Ribeiro de Castro Ferreira, Maria Angelina de Sá Palma, Lúcio Lara Santos, Luís Carlos Oliveira Lima, Wengang Chai, Michael Bachmann
  • Patent number: 11345754
    Abstract: A monoclonal antibody or a derivative thereof which can antagonize and inhibit the binding of human PD-1 antigen to its ligand: the amino acid sequences of CDR1, CDR 2 and CDR 3 in the light chain variable region of the antibody are shown in SEQ ID NO:3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively, while the amino acid sequences of CDR 1, CDR 2 and CDR 3 in the heavy chain variable region are shown in SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, respectively. A humanization preparation process for the antibody and the amino acid sequences of the heavy chain variable region and light chain variable region of the humanized antibody.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: May 31, 2022
    Assignee: AcroImmune Biopharma Co., Ltd.
    Inventors: Hongqun Hu, Zui Chen, Xiaoqi Song, Shiping Luo, Mingwen Cai, Jinling Fan, Yiqing Xu, Qunmin Zhou
  • Patent number: 11327076
    Abstract: The present invention relates to methods of diagnosing breast cancer in a patient, as well as methods of monitoring the progression of breast cancer and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: May 10, 2022
    Assignee: Meso Scale Technologies, LLC.
    Inventors: Simone Barbero, Eli N. Glezer, Anu Mathew